As the medical field continues to evolve, targeted therapy has emerged as a promising advancement in oncology. This innovative approach has revolutionized cancer treatment by focusing on specific proteins and genes associated with cancer growth, differentiating it from traditional chemotherapy methods.
Advancements in molecular biology and genomics have paved the way for the development of targeted therapies. These therapies are designed to inhibit the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth. The discovery of various molecular targets such as EGFR, ALK, and PD-1/PD-L1 has led to the development of numerous targeted therapies, offering hope to patients with various types of cancer.
Targeted therapy has found widespread application in oncology. It has proven effective in treating various types of cancer including lung, breast, colorectal, and melanoma. For instance, Trastuzumab (Herceptin) targets HER2 protein in breast cancer, while Imatinib (Gleevec) targets BCR-ABL protein in Chronic Myeloid Leukemia. These therapies have shown significant improvement in patient survival and quality of life.
Despite the promise of targeted therapy, challenges remain. Resistance to therapy is a significant issue, often resulting from mutations in target genes. Moreover, the high cost of these therapies can limit their accessibility. However, ongoing research aims to overcome these challenges, with the development of next-generation targeted therapies and combination strategies that can circumvent resistance and enhance efficacy.
Targeted therapy has revolutionized oncology, providing a more precise and effective approach to cancer treatment. Despite existing challenges, the future of targeted therapy is promising, with ongoing research likely to yield even more effective and accessible treatments. As such, it is crucial for medical professionals to stay abreast of these advancements to provide optimal care to their patients.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation